Posted by Michael Wonder on 02 Jul 2016
EMA publishes EPAR for opicapone (Omentys)
1 June 2016 - The EMA has published an EPAR for Bial - Portela's opicapone (Omentys).
Opicapone was approved by the European Commission on 24 June 2016 for use as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
Opicapone will be subjected to additional monitoring by the EMA.
